These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32327174)

  • 41. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
    Wu J; Lin Z
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
    Gou Q; Gou Q; Gan X; Xie Y
    Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer.
    Lee SY; Kim YC; Lee KY; Lee SY; Lee SY; Lee MK; Lee JE; Jang SH; Jang TW; Choi CM
    Thorac Cancer; 2022 Feb; 13(3):380-385. PubMed ID: 34881519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer].
    Gálffy G
    Magy Onkol; 2020 Sep; 64(3):196-204. PubMed ID: 32966350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updates in the molecular pathology of non-small cell lung cancer.
    Paver E; O'Toole S; Cheng XM; Mahar A; Cooper WA
    Semin Diagn Pathol; 2021 Sep; 38(5):54-61. PubMed ID: 33985831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations.
    Dhakar R; Dakal TC; Sharma A
    Genomics; 2022 Jul; 114(4):110401. PubMed ID: 35709927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1].
    Wu D; Li J; Yao MH; Zheng YH; Feng CY; Yang YH
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):251-253. PubMed ID: 33677892
    [No Abstract]   [Full Text] [Related]  

  • 48. Targeted Therapy for Non-Small Cell Lung Cancer.
    Noor ZS; Cummings AL; Johnson MM; Spiegel ML; Goldman JW
    Semin Respir Crit Care Med; 2020 Jun; 41(3):409-434. PubMed ID: 32450595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
    Saw SPL; Le X; Hendriks LEL; Remon J
    Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
    Nadler E; Vasudevan A; Wang Y; Ogale S
    Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer.
    Dolgin E
    Nature; 2020 Nov; 587(7834):S16-S17. PubMed ID: 33208972
    [No Abstract]   [Full Text] [Related]  

  • 52. Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
    Lim SM; Lee JB; Oya Y; Nutzinger J; Soo R
    JCO Oncol Pract; 2024 Jan; 20(1):47-56. PubMed ID: 37733983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC.
    Tripathi V; Khare A; Shukla D; Bharadwaj S; Kirtipal N; Ranjan V
    Int Immunopharmacol; 2024 Sep; 139():112682. PubMed ID: 39029228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rare molecular subtypes of lung cancer.
    Harada G; Yang SR; Cocco E; Drilon A
    Nat Rev Clin Oncol; 2023 Apr; 20(4):229-249. PubMed ID: 36806787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
    Imyanitov EN; Iyevleva AG; Levchenko EV
    Crit Rev Oncol Hematol; 2021 Jan; 157():103194. PubMed ID: 33316418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
    Calvo V; Camps C; Carcereny E; Cobo M; Dómine M; García Campelo MR; González Larriba JL; Guirado M; Hernando-Trancho F; Massutí B; Nadal E; Rodríguez-Abreu D; Sánchez A; Sullivan IG; Provencio M;
    Clin Transl Oncol; 2024 Mar; 26(3):597-612. PubMed ID: 37651020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted therapy of non-small cell lung cancer.
    Svaton M
    Klin Onkol; 2021; 34(Supplementum 1):48-52. PubMed ID: 34154330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell Lung Cancer.
    Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
    Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases.
    Zheng J; Zhou JY; Bao Z; Shen Q; Cao H; Zhou JY
    Chin Med J (Engl); 2020 Jul; 133(14):1725-1726. PubMed ID: 32558701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.